Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,090 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07120529Recruiting
Comparing two types of hysterectomy for early cervical cancer
This study looks at two ways to remove the uterus and cervix for early-stage cervical cancer: minimally invasive surgery (like laparoscopic or robotic) versus open surgery (traditional large incision). It checks whether the less invasive approach works just as well in terms of survival and keeping the cancer from coming back.
BialystokAges 18–85 - NCT07115992Recruiting
Surgery with or without radiation for prostate cancer
This trial compares radical prostatectomy (surgery to remove the prostate) alone versus surgery plus pelvic lymph node removal, with or without additional radiation, for men with intermediate- or high-risk prostate cancer that has not spread. It aims to see which approach is more effective and safe.
ShanghaiAges 18–80 - NCT07123545RecruitingPhase 1/Phase 2
Personalized T-cell therapy for advanced liver cancer
This trial tests a personalized treatment using your own immune cells (T-cells) trained to attack specific markers on your liver cancer. It is for people with advanced liver cancer that has worsened after at least two prior treatments and who have tumor tissue available for genetic testing.
Hangzhou, ZhejiangAges 18–75 - NCT06966232RecruitingPhase 3
Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT07106814RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy (Meta10-TIL) made from your own immune cells that were trained to attack cancer. It is for people with advanced solid tumors that have stopped responding to standard treatments, including cervical, liver, lung, breast, ovarian, head and neck, or colorectal cancer.
Hefei, AnhuiAges 19–70 - NCT07113925RecruitingPhase 1
Testing TQB2101 for advanced blood cancers
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
Zhengzhou, HenanAges 18–75 - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Sarasota, FloridaAges 18 years+ - NCT07110883RecruitingPhase 1
Study of SYS6023 for advanced solid tumors
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
Harbin, HeilongjiangAges 18 years+ - NCT07110584RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called MDX2004 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if the drug is safe and if it helps shrink tumors.
Liverpool, New South WalesAges 18 years+ - NCT07111546RecruitingPhase 2
A study of LBL-024 combination for advanced solid tumors
This trial tests a new drug combination (LBL-024) for people with advanced solid tumors, including bile duct and liver cancers. It aims to see if the treatment is safe and effective for those who have not responded to other therapies.
Hefei, AnhuiAges 18–75 - NCT07108348Recruiting
ADAR1 levels in rectal cancer
This study looks at a protein called ADAR1 in rectal cancer tissue. It aims to see how ADAR1 levels might be related to the cancer and help doctors understand the disease better.
Konya, MeramAges 18–90 - NCT07111455Recruiting
Oral bacteria changes with chemoimmunotherapy for mouth cancer
This study is testing whether a combination of chemotherapy and immunotherapy before surgery can help treat advanced oral cancer. Researchers will also look at how the cancer changes the bacteria in your mouth.
Guangzhou, GuangdongAges 18–80 - NCT06307925RecruitingPhase 1
HC010 for advanced solid tumors: a safety and early efficacy study
This trial is testing a new drug (HC010) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe, how it works in the body, and whether it can shrink tumors.
Guangzhou, GuangdongAges 18–75 - NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT07097935RecruitingPhase 1/Phase 2
Study of HS-10516 combo therapy for advanced kidney cancer
This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07100249RecruitingPhase 1
Study of HDM2012 for advanced solid tumors
This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.
ShanghaiAges 18–75 - NCT07099430RecruitingPhase 1/Phase 2
Study of LBL-024 alone or with LBL-007 or toripalimab for advanced melanoma
This trial tests a new drug, LBL-024, either by itself or combined with another drug (LBL-007 or toripalimab) in people with advanced melanoma. The goal is to see if these combinations can shrink tumors or slow cancer growth.
Fuzhou, FujianAges 18 years+ - NCT07098338RecruitingPhase 2
New drug combos for advanced lung cancer
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
Santa Monica, CaliforniaAges 18 years+ - NCT07093970RecruitingPhase 1/Phase 2
MRG006A for advanced solid tumors
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
Beijing, Beijing MunicipalityAges 17–85 - NCT07094204RecruitingPhase 1
Study of ASP5834 for advanced solid tumors with KRAS changes
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
Santa Monica, CaliforniaAges 18 years+ - NCT07087223RecruitingPhase 1/Phase 2
Study of vebreltinib plus furmonertinib for NSCLC with c-Met amplification
This trial tests a combination of two targeted therapies (vebreltinib and furmonertinib) for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a change called c-Met amplification and has stopped responding to earlier EGFR-targeted treatment. It aims to see if adding vebreltinib can help control the cancer.
Neimeng, NeimengAges 18 years+ - NCT07088809Enrolling by invitation
Nanoparticles with Platelet-Rich Fibrin for Gum Recession
This trial tests a new material to treat gum recession—tiny particles mixed with your own blood components (platelet-rich fibrin) placed as a membrane. The goal is to see if it helps cover exposed roots and improve gum health.
Tanta, Gharbia GovernorateAges 20–45 - NCT07079228RecruitingPhase 3
Comparing a new drug with chemo for pancreatic cancer
This trial tests a new treatment called QLS31905 plus chemotherapy against a placebo plus chemotherapy for people with advanced pancreatic cancer that hasn't been treated yet. It aims to see if the new combination works better.
BeijingAges 18–75
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,090 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.